%0 Review
%T Bone marrow stromal cell antigen 2: Tumor biology, signaling pathway and therapeutic targeting (Review).
%A Yu H
%A Bian Q
%A Wang X
%A Wang X
%A Lai L
%A Wu Z
%A Zhao Z
%A Ban B
%J Oncol Rep
%V 51
%N 3
%D 2024 Mar
%M 38240088
%F 4.136
%R 10.3892/or.2024.8704
%X Bone marrow stromal cell antigen 2 (BST2) is a type II transmembrane protein that serves critical roles in antiretroviral defense in the innate immune response. In addition, it has been suggested that BST2 is highly expressed in various types of human cancer and high BST2 expression is related to different clinicopathological parameters in cancer. The molecular mechanism underlying BST2 as a potential tumor biomarker in human solid tumors has been reported on; however, to the best of our knowledge, there has been no review published on the molecular mechanism of BST2 in human solid tumors. The present review focuses on human BST2 expression, structure and functions; the molecular mechanisms of BST2 in breast cancer, hepatocellular carcinoma, gastrointestinal tumor and other solid tumors; the therapeutic potential of BST2; and the possibility of BST2 as a potential marker. BST2 is involved in cell membrane integrity and lipid raft formation, which can activate epidermal growth factor receptor signaling pathways, providing a potential mechanistic link between BST2 and tumorigenesis. Notably, BST2 may be considered a universal tumor biomarker and a potential therapeutical target.